Although endocrine therapy by using oestrogen antagonist tamoxifen can effectively improve the survival rates of oestrogen receptor-alpha (ERα) positive breast cancer patients, however a large proportion of patients are resistant to tamoxifen therapy. Here, ESR1 is linked to breast cancer.